adenosine has been researched along with Hematologic Malignancies in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Li, F; Xu, YL; Yang, FF | 1 |
| Jiang, X; Jin, Z; Wang, P; Wu, X; Xiao, Y; Zheng, J | 1 |
| Chen, J; Qing, Y; Su, R | 1 |
| Tsukamoto, H | 1 |
| Cartron, G; Cavalli, G; Herviou, L; Klein, B; Moreaux, J | 1 |
| Feng, G; Gandhi, V; Krett, NL; McBrayer, SK; Qian, J; Rosen, ST; Shanmugam, M; Yarrington, M | 1 |
| Anderlini, P; Andersson, BS; Andreeff, M; Braunschweig, I; Bruton, J; Champlin, R; Claxton, D; Cohen, A; Davis, M; Donato, M; Gajewski, J; Giralt, S; Ippolitti, C; Khouri, I; Kornblau, S; Molldrem, J; Przepiorka, D; Thall, PF; Ueno, NT; Wang, X | 1 |
5 review(s) available for adenosine and Hematologic Malignancies
| Article | Year |
|---|---|
[Research Progress of m6A Methylation Modification in Hematological Tumors--Review].
Topics: Adenosine; Epigenesis, Genetic; Hematologic Neoplasms; Humans; Methylation; Neoplasms; RNA, Messenger | 2022 |
The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy.
Topics: 5'-Nucleotidase; Adenosine; Adenosine Monophosphate; Hematologic Neoplasms; Humans; Immunosuppressive Agents; T-Lymphocytes; Tumor Microenvironment | 2023 |
RNA modifications in hematopoietic malignancies: a new research frontier.
Topics: Adenosine; Hematologic Neoplasms; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Methylation; RNA Processing, Post-Transcriptional; RNA, Neoplasm | 2021 |
[Extracellular adenosine is a therapeutic target for limiting graft-versus-host disease and enhancing the graft-versus-tumor effect against hematopoietic malignancy].
Topics: 5'-Nucleotidase; Adenosine; Animals; Extracellular Space; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans | 2014 |
EZH2 in normal hematopoiesis and hematological malignancies.
Topics: Adenosine; B-Lymphocytes; Cell Differentiation; Cell Proliferation; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Ethylenediamines; Gene Expression Regulation; Hematologic Neoplasms; Hematopoiesis; Hematopoietic Stem Cells; Histones; Humans; Indoles; Methylation; Polycomb Repressive Complex 2; Precision Medicine; Pyrazoles; Pyridones | 2016 |
1 trial(s) available for adenosine and Hematologic Malignancies
| Article | Year |
|---|---|
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.
Topics: Acute Disease; Adenosine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cladribine; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
1 other study(ies) available for adenosine and Hematologic Malignancies
| Article | Year |
|---|---|
Integrative gene expression profiling reveals G6PD-mediated resistance to RNA-directed nucleoside analogues in B-cell neoplasms.
Topics: 2-Chloroadenosine; Adenosine; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gene Expression Profiling; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glucosephosphate Dehydrogenase; Hematologic Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Multiple Myeloma; Neoplasm Proteins; Pentose Phosphate Pathway; RNA, Neoplasm | 2012 |